Your fact-checks will appear here
Experimental drug for the treatment of Alzheimer's disease
No reliable information about a therapy called "memo blast" is present in the supplied reporting, so its effects cannot be judged from these sources; the documents instead evaluate anti-amyloid monocl...
Recent Phase III readouts show a clear group‑level relationship: antibodies that produce large, sustained reductions in amyloid PET signal have tended to produce modest but statistically significant s...
APOE‑ε4 carrier status meaningfully raises the risk of amyloid‑related imaging abnormalities (ARIA) with both lecanemab and donanemab, and that elevated risk has been translated into mandatory APOE ge...
Lecanemab and donanemab are two recently approved anti‑amyloid monoclonal antibodies tested in large, randomized trials in early Alzheimer’s disease that both produced substantial amyloid PET clearanc...
Two monoclonal antibodies—lecanemab (Leqembi) and donanemab (Kisunla)—offer modest slowing of early Alzheimer’s symptoms but carry specific, sometimes serious safety risks that require structured moni...
shows its clearest, largest subgroup benefit in patients with low-to-medium baseline burden (the “earlier” tau stage), with subgroup analyses reporting roughly one-third slower clinical decline and hi...
Lecanemab and donanemab are monoclonal anti‑amyloid antibodies approved for early Alzheimer’s disease that produce modest slowing of decline but carry important and common safety risks—most notably am...
The randomized trials of lecanemab and donanemab showed statistically significant slowing of cognitive and functional decline over 18 months, but the absolute differences were small versus placebo and...